PDS Biotechnology Corp PDSB

Healthcare Biotechnology

PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.

NDAQ:PDSB - Post by User

PDS Biotechnology Corp

Bullboard Posts

Next >>

Post by schoolofrockon Sep 30, 2020 1:49pm

94 Views

Post# 31642689

PDSB - Oct 6th - Virtual Roadshow

Save the date - Oct 6th - Virtual roadshow with PDS Biotechnology CEO Frank Bedu-Addo. Tune in, ask questions, no charge.

https://attendee.gotowebinar.com/register/6143026848552840720

User image